Crescent Biopharma Inc CBIO.OQ CBIO.O is expected to show no change in quarterly revenue when it reports results on August 1 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Crescent Biopharma Inc is for a loss of $1.76 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Crescent Biopharma Inc is $27.00, about 54.4% above its last closing price of $12.30
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -5.00 | -5.00 | -4.00 | Beat | 20 |
2025 | -11.20 | ||||
-26.00 | | ||||
Jun. 30 2024 | -16.19 | -16.75 | -16.00 | Beat | 4.5 |
Mar. 31 2024 | -17.00 | -16.50 | -17.00 | Missed | -3 |
Dec. 31 2023 | -15.00 | -15.25 | -14.00 | Beat | 8.2 |
Sep. 30 2023 | -14.11 | -14.33 | -14.00 | Beat | 2.3 |
Jun. 30 2023 | -17.81 | -18.33 | -13.00 | Beat | 29.1 |
This summary was machine generated July 30 at 11:09 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。